Fostriecin-mediated G2-M-phase growth arrest correlates with abnormal centrosome replication, the formation of aberrant mitotic spindles, and the inhibition of serine/threonine protein phosphatase activity

Cancer Research

Volumn 58, Issue 16, 1998, Pages 3611-3619

  Cheng, Aiyang ^a   Balczon, Ron ^a   Zuo, Zhuang ^a   Koons, Jamie S ^a   Walsh, Aimée H ^a   Honkanen, Richard E ^a  

^a UNIVERSITY OF SOUTH ALABAMA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANTHARIDIN; DNA; DNA TOPOISOMERASE (ATP HYDROLYSING); FOSTRIECIN; OKADAIC ACID; PHOSPHOPROTEIN PHOSPHATASE; ALKENE; ANTINEOPLASTIC AGENT; ENZYME INHIBITOR; MESSENGER RNA; PROTEIN P53; PROTEIN SERINE THREONINE PHOSPHATASE; PROTEIN-SERINE-THREONINE PHOSPHATASE; PYRONE DERIVATIVE;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL CYCLE G2 PHASE; CENTROSOME; CHO CELL; CONFOCAL LASER MICROSCOPY; DOSE RESPONSE; ENZYME ACTIVITY; ENZYME INHIBITION; IMMUNOFLUORESCENCE MICROSCOPY; IMMUNOHISTOCHEMISTRY; MITOSIS SPINDLE; NONHUMAN; PRIORITY JOURNAL; ANIMAL; DRUG ANTAGONISM; DRUG EFFECT; ENZYMOLOGY; HAMSTER; METABOLISM; MITOSIS;

ALKENES; ANIMALS; ANTINEOPLASTIC AGENTS; CANTHARIDIN; CENTROSOME; CHO CELLS; CRICETINAE; ENZYME INHIBITORS; G2 PHASE; MITOSIS; MITOTIC SPINDLE APPARATUS; OKADAIC ACID; PHOSPHOPROTEIN PHOSPHATASE; PYRONES; RNA, MESSENGER; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0032528624     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (70)

1. Stampwala, S. S., Bunge, R. H., Hurley, T. R., Willmer, N. E., Brankiewicz, A. J., Steinman, C. E., Smitka, T. A., and French, J, C. Novel antitumor agents CI-920, PD 113,270 and PD 113,271. II. Isolation and characterization. J. Antibiot. (Tokyo), 36: 1601-1605, 1983.
2. Scheithauer, W., Von Hoff, D. D., Clark, G. M., Shillis, J. L., and Elslager, E. F. In vitro activity of the novel antitumor antibiotic fostriecin (CI-920) in a human tumor cloning assay. Eur. J. Cancer Clin. Oncol., 22: 921-926, 1986.
3. Jackson, R. C., Fry, D. W., Boritzki, T. J., Roberts, B. J., Hook, K. E., and Leopold, W. R. The biochemical pharmacology of CI-920, a structurally novel antibiotic with antileukemic activity. Adv. Enzyme Regul., 23: 193-215, 1985.
4. Tunac, J. B., Graham, B. D., and Dobson, W. E. Novel antitumor agents CI-920, PD 113, 270 and PD 113, 271. I. Taxonomy, fermentation and biological properties. J. Antibiot. (Tokyo), 36: 1595-1600, 1983.
5. Leopold, W. R., Shillis, J. L., Mertus, A. E., Nelson, J. M., Roberts, B. J., and Jackson, R. C. Anticancer activity of the structurally novel antibiotic CI-920 and its analogues. Cancer Res., 44: 1928-1932, 1984.
6. de Jong, R. S., de Vries, E. G., and Mulder, N. H. Fostriecin: a review of the preclinical data. Anticancer Drugs, 8: 413-418, 1997.
7. Fry, D. W., Boritzki, T. J., and Jackson, R. C. Studies on the biochemical mechanism of the novel antitumor agent, CI-920. Cancer Chemother. Pharmacol., 13: 171-175, 1984.
8. Boritzki, T. J., Wolfard, T. S., Besserer, J. A., Jackson, R. C., and Fry, D. W. Inhibition of type II topoisomerase by fostriecin. Biochem. Pharmacol., 37: 4063-4068, 1988.
9. Chen, M., and Beck, W. T. Teniposide-resistant CEM cells, which express mutant DNA topoisomerase IIα when treated with non-complex-stabilizing inhibitors of the enzyme, display no cross-resistance and reveal aberrant functions of the mutant enzyme. Cancer Res., 53: 5946-5953, 1993.
10. Fattman, C. L., Allan, W. P., Hasinoff, B. B., and Yalowich, J. C. Collateral sensitivity to the bisdioxopiperazine dexrazoxane (ICRF-187) in etoposide (VP-16)-resistant human leukemia K562 cells. Biochem. Pharmacol., 52: 635-642, 1996.
11. Roberge, M., Tudan, C., Hung, S. M. F., Harder, K. W., Jirik, F. R., and Anderson, H. Antitumor drug fostriecin inhibits the mitotic entry checkpoint and protein phosphatases 1 and 2A. Cancer Res., 54: 6115-6121, 1994.
12. cdc2 kinase activity and histone H1 hyperphosphorylation, but is associated with enhanced histone H2A and H3 phosphorylation. EMBO J., 14: 976-985, 1995.
13. Ho, D. T., and Roberge, M. The antitumor drug fostriecin induces vimentin hyperphosphorylation and intermediate filament reorganization. Carcinogenesis (Lond.), 17: 967-972, 1996.
14. Walsh, A. H., Cheng, A., and Honkanen, R. E. Fostriecin, an antitumor antibiotic with inhibitory activity against serine/threonine protein phosphatases types 1 (PP1) and 2A (PP2A), is highly selective for PP2A. FEBS Lett., 416: 230-234, 1997.
15. Cohen, P., Holmes, C. F. B., and Tsukitani, Y. Okadaic acid: a new probe for the study of cellular regulation. Trends Biochem. Sci., 15: 98-102, 1990.
16. Honkanen, R. E., Codispoti, B. A., Tse, K., and Boynton, A. L. Characterization of natural toxins with inhibitory activity against serine/threonine protein phosphatases. Toxicon, 32: 339-350, 1994.
17. Honkanen, R. E. Cantharidin, another natural toxin that inhibits the activity of serine/threonine protein phosphatases types 1 and 2A. FEBS Lett. 330: 283-286, 1993.
18. Honkanen, R. E., Zwiller, J., Moore, R. E., Daily, S. L., Khatra, B. S., Dukelow, M., and Boynton, A. L. Characterization of microcystin-LR: a potent inhibitor of Type 1 and Type 2A protein phosphatases. J. Biol. Chem., 265: 19401-19404, 1990.
19. Critz, S. D., and Honkanen, R. E. Protein phosphatases and their role in the regulation of membrane currents in sensory neurons of Aplysia. Neuroprotocols: a companion to methods in neurosciences, 6: 78-83, 1995.
20. Honkanen, R. E., Dukelow, M., Moore, R. E., Zwiller, J., Khatra, B. S., and Boynton, A. L. Cyanobacterial nodularin is a potent inhibitor of Type 1 and Type 2A protein phosphatases. Mol. Pharmacol. 40: 577-583, 1991.
21. , = 70,000. J. Biol. Chem., 260: 4295-4302, 1985.
22. Pallas, D. C., Shahrink, L. K., Martin, B. L., Jaspers, S., Miller, T. B., Brautigan, D. L., and Roberts, T. M. Polyoma small and middle T antigens and SV40 small t antigen form stable complexes with protein phosphatase 2A. Cell, 60: 167-176, 1990.
23. Killilea, S. D., Aylward, J. H., Mellgren, R. L., and Lee, E. Y. C. Purification and properties of bovine myocardial phosphorylase phosphatase (protein phosphatase C). Arch. Biochem. Biophys., 191: 638-646, 1978.
24. Funkhouser, J. D., Cheshire, L. B., Read, R. J., Hester, R. B., and Peterson, R. D. Monoclonal antibody isolation of type II pneumocytes. Cytometry, 8: 321-326, 1987.
25. Balczon, R., and Brinkley, B. R. Tubulin interaction with kinetochore proteins: analysis by in vitro assembly and chemical cross-linking. J. Cell Biol., 105: 855-862, 1987.
26. Balczon, R., and West, K. The identification of mammalian centrosomal antigens using human autoimmune anticentrosome antisera. Cell Motil. Cytoskeleton, 20: 121-135, 1991.
27. Balczon, R., Bao, L., and Zimmer, W. E. PCM-1, a 228-kD centrosome autoantigen with a distinct cell cycle distribution. J. Cell Biol., 124: 783-793, 1994.
28. King, J. A. C., Hester, R. B., Titford, M. E., and Michael, C. Psammoma bodies: confocal microscopy with 3-D reconstruction of two-color fluorescence on paraffin-embedded sections and cytology smears. Cell Vis., 2: 420-424, 1995.
29. Hotz, M. A., Traganos, P., and Darzynkiewicz, Z. Changes in nuclear chromatin related to apoptosis or necrosis induced by the DNA topoisomerase II inhibitor fostriecin in MOLT-4 and HL-60 cells are revealed by altered DNA sensitivity to denaturation. Exp. Cell Res., 201: 184-191, 1992.
30. Gorczyca, W., Bigman, K., Mittelman, A., Ahmed, T., Gong, J., Melamed, M. R., and Darzynkiewicz, Z. Induction of DNA strand breaks associated with apoptosis during treatment of leukemias. Leukemia (Baltimore), 7: 659-670, 1993.
31. Gorczyca, W., Gong, J., Ardelt, B., Traganos, F., and Darzynkiewicz, Z. The cell cycle related differences in susceptibility of HL-60 cells to apoptosis induced by various antitumor agents. Cancer Res., 53: 3186-3192, 1993.
32. Morana, S. J., Wolf, C. M., Li, J., Reynolds, J. E., Brown, M. K., and Eastman, A. The involvement of protein phosphatases in the activation of ICE/CED-3 protease, intracellular acidification, DNA digestion, and apoptosis. J. Biol. Chem. 271: 18263-18271, 1996.
33. Kiguchi, K., Glesne, D., Chubb, H., Fujiki, H., and Huberman, E. Differential induction of apoptosis in human breast tumor cells by okadaic acid and related inhibitors of protein phosphatases 1 and 2A. Cell Growth Differ. 5: 995-1004, 1994.
34. Robaye, B., Doskeland, A. P., Suarez-Huerta, N., Doskeland, S. O., and Dumont, J. E. Apoptotic cell death analyzed at the molecular level by two-dimensional gel electrophoresis. Electrophoresis, 15: 503-510, 1994.
35. Jordan, M. A., Wendell, K., Gardiner, S., Derry, W. B., Copp, H., and Wilson, L. Mitotic block induced in HeLa cells by low concentrations of paclitaxel (Taxol) results in abnormal mitotic exit and apoptotic cell death. Cancer Res., 56: 816-825, 1996.
36. Crossin, K. L., and Carney, D. H. Microtubule stabilization by Taxol inhibits initiation of DNA synthesis by thrombin and by epidermal growth factor. Cell, 27: 341-350, 1981.
37. Osborn, T. G., Patel, N. J., Ross, S. C., and Bauer, N. E. Antinuclear antibody staining only centrioles in a patient with scleroderma. N. Engl. J. Med., 307: 253-254, 1982.
38. Fukasawa, K., Choi, T., Kuriyama, R., Rulong, S., and Vande Woude, G. F. Abnormal centrosome amplification in the absence of p53. Science (Washington, DC), 271: 1744-1747, 1996.
39. Levine, D. S., Sanchez, C. A., Rabinovitch, P. S., and Reid, B. J. Formation of the tetraploid intermediate is associated with the development of cells with more than four centrioles in the elastase-simian virus 40 tumor antigen transgenic mouse model of pancreatic cancer. Proc. Natl. Acad. Sci. USA, 88: 6427-6431, 1991.
40. Cross, S. M., Sanchez, C. A., Morgan, C. A., Schimke, M. K., Ramel, S., Idzerda, R. L., Raskind, W. H., and Reid, B. J. A p53-dependent mouse spindle checkpoint. Science (Washington DC), 267: 1353-1356, 1995.
41. Skouv, J., Jensen, P. Ø., Forchhammer, J., Larsen, J. K., and Lund, L. Tumorpromoting phorbol ester transiently down-modulates the p53 level and blocks the cell cycle. Cell Growth Differ., 5: 329-340, 1994.
42. Walter, G., and Mumby, M. Protein serine/threonine phosphatases and cell transformation. Biochim. Biophys. Acta, 1155: 207-226, 1993.
43. Susick, R. L., Jr., Hawkins, K. L., and Pegg, D. G. Preclinical toxicological evaluation of fostriecin, a novel anticancer antibiotic, in rats. Fundam. Appl. Toxicol., 15: 258-269, 1990.
44. Brewis, N. D., Street, A. J., Prescott, A. R., and Cohen, P. T. W. PPX, a novel protein serine/threonine phosphatase localized to centrosomes. EMBO J., 12: 987-996, 1993.
45. Huang, X., Cheng, A., and Honkanen, R. E. Genomic organization of the human PP4 gene encoding a serine/threonine protein phosphatase (PP4) suggest a common ancestry with PP2A. Genomics, 44: 336-343, 1997.
46. Chen, M. X., McPartlin, A. E., Brown, L., Chen, Y. H., Barker, H. M., and Cohen, P. T. W. A novel human protein serine/threonine phosphatase, which possesses four tetratricopeptide repeat motifs and localizes to the nucleus. EMBO J., 12: 4278-4290, 1994.
47. Bastians, H., and Ponstingl, H. The novel human protein serine/threonine phosphatase 6 is a functional homologue of budding yeast Sit4p and fission yeast ppe1, which are involved in cell cycle regulation. J. Cell Sci., 109: 2865-2874, 1996.
48. Huang, X., and Honkanen, R. E. Molecular cloning, expression, and characterization of a novel human serine/threonine protein phosphatase, PP7, that is homologous to Drosophila retinal degeneration C gene product (rdgC). J. Biol. Chem., 273: 12250-12258, 1998.
49. Centonze, V. E., and Borisy, G. G. Nucleation of microtubules from mitotic centrosomes is modulated by a phosphorylated epitope. J. Cell Sci., 95: 405-411, 1990.
50. + in fission yeast mitotic control. Cell, 57: 1009-1016, 1989.
51. Doonan, J. H., and Morris, N. R. The bimG gene of Aspergillus nidulans, required for completion of anaphase, encodes a homolog of mammalian phosphoprotein phosphatase 1. Cell, 57: 987-996, 1989.
52. + gene required for chromosome disjoining encodes one of two putative type 1 protein phosphatases. Cell, 57: 997-1007, 1989.
53. Ohkura, H., and Yanagida, M. S. pombe gene sds22+ essential for a midmitotic transition encodes a leucine-rich repeat protein that positively modulates protein phosphatase-1. Cell, 64: 149-157, 1991.
54. Kinoshita, N., Ohkura, H., and Yanagida, M. Distinct, essential roles of type 1 and 2A protein phosphatases in the control of the fission yeast cell division cycle. Cell, 63: 405-415, 1990.
55. Axton, J. M, Dombradi, V., Cohen, P. T., and Glover, D. M. One of the protein phosphatase I isoenzymes in Drosophila is essential for mitosis. Cell, 63: 33-46, 1990.
56. Fernandez, A., Brautigan, D. L., Lamb, N. J. Protein phosphatase type 1 in mammalian cell mitosis: chromosomal localization and involvement in mitotic exit. J. Cell Biol., 116: 1421-1430, 1992.
57. Vandre, D. D., Davis, F. M., Rao, P. N., and Borisy, G. G. Phosphoproteins are components of mitotic microtubule organizing centers. Proc. Natl. Acad. Sci . USA, 81: 4439-4443, 1984.
58. Van Dolah, F. M., and Ramsdell, J. S. Okadaic acid inhibits a protein phosphatase activity involved in formation of the mitotic spindle of GH4 rat pituitary cells. J. Cell. Physiol., 152: 190-198, 1992.
59. Tournebize, R., Andersen, S. S., Verde, F, Doree, M., Karsenti, E., and Hyman, A. A. Distinct roles of PP1 and PP2A-like phosphatases in control of microtubule dynamics during mitosis. EMBO J., 16: 5537-5549, 1997.
60. Snaith, H. A., Armstrong, C. G., Guo, Y., Kaiser, K., and Cohen, P. T. Deficiency of protein phosphatase 2A uncouples the nuclear and centrosome cycles and prevents attachment of microtubules to the kinetochore in Drosophila microtubule star (mts) embryos. J. Cell Sci., 109: 3001-3012, 1996.
61. Suganuma, M., Fujiki, H., Suguri, H., Yoshizawa, S., Hirota, M., Nakayasu, M., Ojika, M., Wakamatsu, K., Yamada, K., and Sugimura, T. Okadaic acid: an additional non-phorbol-12-tetradecanoate-13-acetate-type tumor promoter. Proc. Natl. Acad. Sci. USA, 85: 1768-1771, 1981.
62. Fujiki, H., Suganuma, M., Yoshizawa, S., Nishiwaki, S., Winyar, B., and Sugimura, T. Mechanisms of action of okadaic acid class tumor promoters on mouse skin. Environ. Health Perspect., 93: 211-214, 1991.
63. Sakai, R., Ikeda, I., Kitani, H., Fujiki, H., Takaku, F., Rapp, U., Sugimura, T., Nagao, M. Flat reversion by okadaic acid of raf and ret-II transformants. Proc. Natl. Acad. Sci. USA, 86: 9946-9950, 1989.
64. Rivedal, E., Mikalsen, S., and Sanner, T. The non-phorbol ester tumor promoter okadaic acid does not promote morphological transformation or inhibit junctional communication in hamster embryo cells. Biochem. Biophys. Res. Commun., 167: 1302-1308, 1990.
65. Mordan, L. J., Dean, N. M., Honkanen, R. E., and Boynton, A. L. Okadaic acid: a reversible inhibitor of neoplastic transformation of mouse fibroblasts. Cancer Commun., 2: 237-241, 1990.
66. 2-M depending on dose. J. Cell. Physiol., 150: 484-492, 1992.
67. Walter, W. G. Antitumor imide derivatives of 7-oxabicyclo[2.2.1]heptane-2,3-dimethyl-2,3-dicarboxylic acid. J. Pharm. Sci., 78: 66-67, 1989.
68. Chen, R., Hua, Z., Yang, J., Han, J., Zhang, S., Lü, F., and Xü, B. Studies on antitumor actions of cantharidin. Chin. Med. J. (Engl. Ed.), 93: 183-187, 1980.
69. Hennings, H., and Boutwell, R. K. Studies on the mechanism of skin tumor promotion. Cancer Res., 30: 312-320, 1970.
70. Hokanson, G. C., and French, J. C. Novel antitumor agent CI-920, PD 113, 270 and PD 113, 271. III: structure determination. J. Org. Chem., 50: 462-466, 1985.